Innate Pharma Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jonathan Dickinson

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	6.1yrs

Recente managementupdates

Recent updates

CEO

Jonathan Dickinson (56 yo)

less than a year

Tenure

Mr. Jonathan E. Dickinson served as Executive Vice President and General Manager of Europe at Incyte Corp. since June 2019 until October 2024. He served as General Manager of Europe/International and Senio...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Yannis Morel	Executive VP	9.6yrs	€599.92k	0.24% € 265.3k
Jonathan Dickinson	Chairman of the Executive Board & CEO	less than a year	geen gegevens	geen gegevens
François Romagné	Founder	no data	geen gegevens	geen gegevens
Eric Vivier	Founder	6.9yrs	geen gegevens	0.26% € 287.2k
Marc Bonneville	Founder	no data	geen gegevens	geen gegevens
Jean Fournié	Founder	no data	geen gegevens	geen gegevens
Alessandro Moretta	Founder	no data	geen gegevens	geen gegevens
Frederic Lombard	Senior VP & CFO	3.7yrs	geen gegevens	0.014% € 15.5k
Sonia Quaratino	Executive VP	less than a year	geen gegevens	geen gegevens
Arvind Sood	Executive VP	less than a year	geen gegevens	geen gegevens
Henry Wheeler	Vice President of Investor Relations & Communication	1.9yrs	geen gegevens	0.0039% € 4.3k
Odile Belzunce	Vice President of Compliance & Operations	5.9yrs	geen gegevens	0.077% € 85.0k

2.8yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IDDA wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mario Sznol	Strategic Advisory Board Member	6.1yrs	geen gegevens	geen gegevens
Olivier Martinez	Member of Supervisory Board	no data	geen gegevens	geen gegevens
Diane Mathis	Strategic Advisory Board	less than a year	geen gegevens	geen gegevens
Gilles Brisson	Independent Member of Supervisory Board	17.5yrs	€29.00k	0.090% € 99.8k
Sally Bennett	Independent Supervisory Board Member	2.6yrs	€45.00k	0.0031% € 3.4k
Jean-Yves Blay	Independent Member of Supervisory Board	7yrs	€29.00k	0.000060% € 66.3
Irina Staatz-Granzer	Independent Chairwoman of Supervisory Board	15.5yrs	€42.00k	0.031% € 34.3k
Pascale Boissel	Independent Vice Chairperson of the Supervisory Board	4.6yrs	€60.00k	0.0012% € 1.4k
Miriam Merad	Chairman of Strategic Advisory Board	6.1yrs	geen gegevens	geen gegevens
Veronique Chabernaud	Independent Member of Supervisory Board	9.7yrs	€48.00k	0.00082% € 906.7
Katy Rezvani	Strategic Advisory Board	less than a year	geen gegevens	geen gegevens
Aurelien Marabelle	Strategic Advisory Board Member	6.1yrs	geen gegevens	geen gegevens

6.1yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IDDA wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).

Innate Pharma Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Innate Pharma S.A., Annual General Meeting, May 22, 2025

Innate Pharma SA Announces Board Changes

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma S.A. Announces Executive Changes

Innate Pharma S.A. Announces Supervisory Board Changes

Recent updates

Innate Pharma S.A., Annual General Meeting, May 22, 2025

Innate Pharma S.A. to Report First Half, 2025 Results on Sep 17, 2025

Innate Pharma SA Announces Board Changes

Araris Biotech AG entered into an agreement to acquire ADC Transglutaminase Conjugation Technology Patents Portfolio from Innate Pharma S.A. (ENXTPA:IPH).

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

Innate Pharma S.A. Announces Executive Changes

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

Innate Pharma SA Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

Innate Pharma S.A. Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Innate Pharma S.A. to Report First Half, 2023 Results on Sep 14, 2023

Innate Pharma SA Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

Innate Pharma S.A. Announces Supervisory Board Changes

Innate Pharma Sa Announces the First Patient Was Dosed in A Phase 1/2 Clinical Trial

Innate Pharma SA Announces That Data from the Phase 2 Expansion Cohort

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd